Arrowstreet Capital, Limited Partnership Regeneron Pharmaceuticals, Inc. Call Options Transaction History
Arrowstreet Capital, Limited Partnership
- $122 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REGN
# of Institutions
1,493Shares Held
85.8MCall Options Held
1.53MPut Options Held
1.44M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.49 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.9 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.93 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.38 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.31 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $74.9B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...